Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2018, Article ID 1672176, 8 pages
https://doi.org/10.1155/2018/1672176
Research Article

Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology

1Biostatistics and Epidemiology Unit, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
2CESP INSERM U1018, Paris-Sud University, 94805 Villejuif, France
3Gastrointestinal Oncology Unit, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
4Gastrointestinal Unit, University Hospital, Reims, France

Correspondence should be addressed to Stefan Michiels; rf.yssuorevatsug@sleihcim.nafets

Received 2 May 2017; Accepted 28 November 2017; Published 11 January 2018

Academic Editor: Lev Klebanov

Copyright © 2018 Matthieu Texier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. D. Von Hoff, “There are no bad anticancer agents, only bad clinical trial designs- twenty-first Richard and Hinda Rosenthal foundation award lecture,” Clinical Cancer Research, vol. 4, no. 5, pp. 1079–1086, 1998. View at Google Scholar · View at Scopus
  2. R. Mick, J. J. Crowley, and R. J. Carroll, “Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint,” Controlled Clinical Trials, vol. 21, no. 4, pp. 343–359, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. D. D. Von Hoff, J. J. Stephenson Jr., P. Rosen et al., “Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4877–4883, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Massard, S. Michiels, C. Ferté et al., “High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial,” Cancer Discovery, vol. 7, no. 6, pp. 586–595, 2017. View at Publisher · View at Google Scholar
  5. M. Schwaederle, B. A. Parker, R. B. Schwab et al., “Precision oncology: The UC San Diego moores cancer center predict experience,” Molecular Cancer Therapeutics, vol. 15, no. 4, pp. 743–752, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Bonetti, M. Zaninelli, R. Leone et al., “Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma,” Annals of Oncology, vol. 12, no. 2, pp. 187–191, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Belin, M. Kamal, C. Mauborgne et al., “Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial,” Annals of Oncology, vol. 28, pp. 592–596, 2017. View at Google Scholar
  8. M. Ducreux, D. Malka, J. Mendiboure et al., “Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): An open-label, randomised, phase 3 trial,” The Lancet Oncology, vol. 12, no. 11, pp. 1032–1044, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Pénichoux, S. Michiels, O. Bouché et al., “Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial,” European Journal of Cancer, vol. 49, no. 8, pp. 1882–1888, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Duchateau and P. Janssen, The frailty model, Springer, New York, NY, USA, 2008.
  11. M. Munda, F. Rotolo, and C. Legrand, “parfm: parametric frailty models in R,” Journal of Statistical Software, vol. 51, no. 11, 2012. View at Publisher · View at Google Scholar
  12. S. Kovalchik and W. Mietlowski, “Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint,” Contemporary Clinical Trials, vol. 32, no. 1, pp. 99–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Dufresne, X. Pivot, C. Tournigand et al., “Impact of chemotherapy beyond the first line in patients with metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 107, no. 2, pp. 275–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. G. Hudgens and G. A. Satten, “Midrank unification of rank tests for exact, tied, and censored data,” Journal of Nonparametric Statistics, vol. 14, no. 5, pp. 569–581, 2002. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  15. W. J. Owen, “A power analysis of tests for paired lifetime data,” Lifetime Data Analysis, vol. 11, no. 2, pp. 233–243, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. EM. Agency, Guideline on the evaluation of anticancer medicinal products in man. European Medicines Agency, 44, 33, 2012.
  17. N. Penel, G. D. Demetri, J. Y. Blay et al., “Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy,” Annals of Oncology, vol. 24, no. 2, Article ID mds470, pp. 537–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Bhattacharya, G. Fyfe, R. J. Gray, and D. J. Sargent, “Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5958–5964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. S. Panageas, L. Ben-Porat, M. N. Dickler, P. B. Chapman, and D. Schrag, “When you look matters: The effect of assessment schedule on progression-free survival,” Journal of the National Cancer Institute, vol. 99, no. 6, pp. 428–432, 2007. View at Publisher · View at Google Scholar · View at Scopus